20 October 2020
A recurring issue with many cancer immunotherapies is the difficulty of delivering the cancer-killing drug to the heart of a tumour.
![](/assets/Uploads/Images/General/Regan-Fu-1__FocusFillWyIwLjAwIiwiMC4wMCIsMTAwLDQ1XQ.jpg)
Dr Regan Fu
The internal environment of a tumour can be very different from the rest of the body, which helps the tumour resist treatment. For example, many tumours are ‘hypoxic,’ or oxygen-poor. A lack of oxygen makes it hard for immune cells and cancer drugs to infiltrate a tumour, and on occasion even suppresses the immune response to the cancer entirely.
Dr Regan Fu, who recently completed his doctoral thesis with Professor Ian Hermans, is assessing immunotherapies in combination with the hypoxia-activated drug tarloxotinib. Through adding a hypoxic trigger that activates in the oxygen-poor intratumoral environments, higher doses of anti-cancer drugs can be delivered.
“Not everyone responds to immunotherapies like checkpoint inhibitors,” says Dr Fu. “Many factors can prevent the generation of robust responses to these treatments. One of the factors is within the tumour microenvironment such as tumour hypoxia. In the hypoxic regions of the tumour, the function of most immune cells are suppressed, therefore preventing the treatment from working.
“By using a hypoxia-actived prodrug, the anti-cancer agent is delivered directly to the hypoxic zones of a solid tumour, where it then becomes active.”
The added benefit of hypoxia-activated drugs is that they are much more tumour-specific, resulting in less damage to healthy tissues surrounding the tumour. Future work is planned to better understand how tarloxotinib interacts with the immune system, with the aim of moving towards clinical trials.
Related articles
![New clinical research aims to reduce stomach cancer rates and disparities in New Zealand](/assets/Uploads/Tom-M-Sciencelens_MG_6532-1__FocusFillWyItMC4wNiIsIi0wLjQwIiw2ODAsNDQ1XQ.jpg)
New clinical research aims to reduce stomach cancer rates and disparities in New Zealand
28 May 2024
![A revolution in cancer care is near; here’s what’s needed to make it happen](/assets/Uploads/Images/General/GLG-Labshot-1__FocusFillWyIwLjAwIiwiMC4wMCIsNjgwLDQ0NV0.jpg)
A revolution in cancer care is near; here’s what’s needed to make it happen
9 May 2024
![Significant milestone reached in first NZ CAR T-cell trial as preparations made for larger phase 2 registration trial](/assets/Uploads/Images/General/IMG_0446__FocusFillWyIwLjAwIiwiMC4wMCIsNjgwLDQ0NV0.jpg)
Significant milestone reached in first NZ CAR T-cell trial as preparations made for larger phase 2 registration trial
25 March 2024
![RNZ: Engineering immune cells to kill cancer](/assets/Uploads/4L04KD5_cancer_collage_jpg__FocusFillWyIwLjAyIiwiLTAuMzIiLDY4MCw0NDVd.jpeg)
RNZ: Engineering immune cells to kill cancer
5 November 2023
![BioOra appoints CAR T-cell therapy pioneer, Professor Carl June to Board](/assets/Uploads/Images/General/Carl-June-high-res-expanded__FocusFillWyIwLjA0IiwiLTAuMjgiLDY4MCw0NDVd.png)
BioOra appoints CAR T-cell therapy pioneer, Professor Carl June to Board
31 October 2023
![In Focus: Mastering the technology behind automated CAR T-cell manufacture](/assets/Uploads/Images/General/40316_CBM4701__FocusFillWyIwLjAwIiwiMC4wMCIsNjgwLDQ0NV0.jpg)
In Focus: Mastering the technology behind automated CAR T-cell manufacture
14 September 2023